- Home
- GOSS vs WLAC Comparison
GOSS vs WLAC Comparison
Compare GOSS & WLAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- WLAC
- Stock Information
- Founded
- GOSS 2015
- WLAC 2024
- Country
- GOSS United States
- WLAC United States
- Employees
- GOSS N/A
- WLAC N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- WLAC
- Sector
- GOSS Health Care
- WLAC
- Exchange
- GOSS Nasdaq
- WLAC Nasdaq
- Market Cap
- GOSS 203.3M
- WLAC 172.6M
- IPO Year
- GOSS 2019
- WLAC 2024
- Fundamental
- Price
- GOSS $1.11
- WLAC $10.06
- Analyst Decision
- GOSS Strong Buy
- WLAC
- Analyst Count
- GOSS 4
- WLAC 0
- Target Price
- GOSS $7.50
- WLAC N/A
- AVG Volume (30 Days)
- GOSS 1.5M
- WLAC 5.3K
- Earning Date
- GOSS 05-20-2025
- WLAC 01-01-0001
- Dividend Yield
- GOSS N/A
- WLAC N/A
- EPS Growth
- GOSS N/A
- WLAC N/A
- EPS
- GOSS N/A
- WLAC N/A
- Revenue
- GOSS $114,701,000.00
- WLAC N/A
- Revenue This Year
- GOSS N/A
- WLAC N/A
- Revenue Next Year
- GOSS $172.31
- WLAC N/A
- P/E Ratio
- GOSS N/A
- WLAC $743.53
- Revenue Growth
- GOSS N/A
- WLAC N/A
- 52 Week Low
- GOSS $0.50
- WLAC $9.80
- 52 Week High
- GOSS $1.55
- WLAC $10.19
- Technical
- Relative Strength Index (RSI)
- GOSS 55.81
- WLAC N/A
- Support Level
- GOSS $1.06
- WLAC N/A
- Resistance Level
- GOSS $1.26
- WLAC N/A
- Average True Range (ATR)
- GOSS 0.11
- WLAC 0.00
- MACD
- GOSS 0.03
- WLAC 0.00
- Stochastic Oscillator
- GOSS 67.95
- WLAC 0.00
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About WLAC Willow Lane Acquisition Corp. Class A Ordinary Shares
Willow Lane Acquisition Corp is a blank check company.